- In July 2024, Sinergium Biotech has been launched new initiative to accelerate the development of mRNA vaccines against avian influenza (H5N1) in low- and middle-income countries. Led by Sinergium Biotech, this project leverages the WHO and Medicines Patent Pool's mRNA Technology Transfer Programme. It aims to enhance manufacturing capacity and bolster pandemic preparedness by sharing technology and expertise with partners
- In January 2024, Ceva Santé Animal announced its acquisition of Scout Bio, a leader in pet biotechnology. This strategic move enhances Ceva's innovation capabilities, providing access to a pipeline of monoclonal antibodies and gene therapies for chronic pet diseases. The acquisition aims to accelerate biotherapeutic advancements while continuing Ceva's commitment to all species
- In October 2023, Sinergium Biotech Argentina and PAHO have signed a technical cooperation agreement to enhance RNA technology transfer for vaccine production. During a meeting with PAHO Director Jarbas Barbosa, Health Minister Carla Vizzotti emphasized the importance of this initiative for advancing vaccine development and reducing regional dependence on external technologies. The agreement aims to strengthen the mRNA ecosystem in Argentina, promoting equitable access to health solutions
- In April 2022, Ceva Santé Animale announced a joint venture with Mitsui, forming Ceva Bussan Animal Health K.K. in Japan. This partnership aims to enhance Ceva's presence in the Japanese market, focusing on food safety and disease control in livestock. Leaders from both companies expressed excitement about accelerating development and collaboration in addressing key industry challenges
